Clinical trial · no report yet · Phase 3
CodeBreaK 202
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- NCT05920356 ↗
- Recruiting
- Amgen
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Podcasts | 5 | |
| YouTube | 4 | |
| X threads | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Sotorasib; Pembrolizumab
- Arms
- Sotorasib combined with carboplatin and pemetrexed · Experimental
- Pembrolizumab combined with carboplatin and pemetrexed · Active comparator
- Enrollment
- 750 (estimated)
- Primary outcomes
- Progression-free Survival (PFS)
- Overall Survival (OS)
- Sponsor
- Amgen
- Start
- Nov 16, 2023
- Primary completion
- Jun 30, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05920356 · updated Oct 13, 2026